RNAC
Cartesian TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
The financing extends runway into 2028 and supports multiple clinical programs, while positive AURORA data could support a mid-2027 BLA filing and materially re-rate the stock.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -5.9.
What can break
AURORA is a binary Phase 3 value inflection with substantial downside if efficacy or safety outcomes disappoint.
Momentum
89
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.50 · Bull $18.00 · Bear $4.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $34.57
Why
Momentum89 · Δ7d -5.9
Value41 · Δ7d -0.1
Sentiment60 · Δ7d -7.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendSoftening
Δ7d
-5.9
Δ21d
-1.6
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
60
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.0
Δ21d
-
Why this grade
Composite grade A. Momentum 88.8 / Value 41.1 / Sentiment 60.4
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$242.69M
Beta
0.45
Shares Out
29.38M
P/E (TTM) · Derived
-1.6
P/S (TTM)
93.25
P/FCF (TTM) · Derived
-2.81
Rev YoY
-92.9%
EPS YoY
+113.4%
Gross Margin
-36.2%
Op Margin
-4748.2%
Net Debt
-$112.46M
Current Ratio
7.65
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology